Literature DB >> 2765637

A two-stage design for choosing among several experimental treatments and a control in clinical trials.

P F Thall1, R Simon, S S Ellenberg.   

Abstract

In clinical trials where several experimental treatments are of interest, the goal may be viewed as identification of the best of these and comparison of that treatment to a standard control therapy. However, it is undesirable to commit patients to a large-scale comparative trial of a new regimen without evidence that its therapeutic success rate is acceptably high. We propose a two-stage design in which patients are first randomized among the experimental treatments, and the single treatment having the highest observed success rate is identified. If this highest rate falls below a fixed cutoff then the trial is terminated. Otherwise, the "best" new treatment is compared to the control at a second stage. Locally optimal values of the cutoff and the stage-1 and stage-2 sample sizes are derived by minimizing expected total sample size. The design has both high power and high probability of terminating early when no experimental treatment is superior to the control. Numerical results for implementing the design are presented, and comparison to Dunnett's (1984, in Design of Experiments: Ranking and Selection, T. J. Santner and A. C. Tamhane (eds), 47-66; New York: Marcel Dekker) optimal one-stage procedure is made.

Entities:  

Mesh:

Year:  1989        PMID: 2765637

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  15 in total

Review 1.  Stopping rules for phase II studies.

Authors:  N Stallard; J Whitehead; S Todd; A Whitehead
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

Review 2.  A review of phase 2-3 clinical trial designs.

Authors:  Peter F Thall
Journal:  Lifetime Data Anal       Date:  2007-09-02       Impact factor: 1.588

Review 3.  Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.

Authors:  Toshimitsu Hamasaki; Scott R Evans; Koko Asakura
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

Review 4.  Randomized phase II trials: a long-term investment with promising returns.

Authors:  Manish R Sharma; Walter M Stadler; Mark J Ratain
Journal:  J Natl Cancer Inst       Date:  2011-06-27       Impact factor: 13.506

5.  Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer.

Authors:  M Méndez; P G Alfonso; E Pujol; E González; C Castañon; P Cerezuela; Y López-Mateos; J J Cruz
Journal:  Invest New Drugs       Date:  2005-06       Impact factor: 3.850

6.  Immunotherapy is different: Implications for vaccine clinical trial design.

Authors:  Richard Simon
Journal:  Hum Vaccin Immunother       Date:  2017-05-12       Impact factor: 3.452

7.  Response adaptive randomization procedures in seamless phase II/III clinical trials.

Authors:  Hongjian Zhu; Jin Piao; J Jack Lee; Feifang Hu; Lixin Zhang
Journal:  J Biopharm Stat       Date:  2019-08-27       Impact factor: 1.051

8.  Phase II cancer clinical trials with heterogeneous patient populations.

Authors:  Sin-Ho Jung; Myron N Chang; Sun J Kang
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

9.  Between-arm comparisons in randomized Phase II trials.

Authors:  Sin-Ho Jung; Stephen L George
Journal:  J Biopharm Stat       Date:  2009       Impact factor: 1.051

10.  Randomized phase II clinical trials.

Authors:  Sin-Ho Jung; Daniel J Sargent
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.